ArticleJournal of clinical medicine2023
The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2024Pooled it
- Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial.BMJ open ophthalmology · 2024Trial
- Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjögren's syndrome: a randomized trial.Scientific reports · 2023Trial
- Autologous platelet-rich plasma versus autologous serum in treatment of dry eye disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Advances in Pharmacotherapy and Physiotherapy for Dry Eye Disease: Molecular Mechanisms and Future Directions-A Narrative Literature Review.International journal of molecular sciences · 2026Review
- Optimizing Autologous Serum Tear Therapy for Dry Eye Disease: Strategies and Innovations.Journal of clinical medicine · 2026Article
- Conjunctival transforming growth factor-β2 and vascular endothelial growth factor in canine keratoconjunctivitis sicca: Baseline alterations, clinical associations, and response to 0.2% cyclosporine therapy.Veterinary world · 2026Article
- Article
- Tear Film Alterations in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Platelets in Dry Eye Disease: A Narrative Review of Biological Mechanisms and Therapeutic Applications Derived from Platelets.Life (Basel, Switzerland) · 2025Review
- Blood Derivatives in the Therapy of Ocular Surface Diseases.International journal of molecular sciences · 2025Review
- Comparative Efficacy of Platelet-Rich Plasma, Autologous Serum, and Artificial Tears in Dry Eye Disease: A Systematic Review and Meta-Analysis.Biomedicines · 2025Review
- Hyperglycemia-Reduced Platelet-Derived Growth Factor-BB Expression Impairs Corneal Wound Healing in Diabetic Mice.Investigative ophthalmology & visual science · 2025Article
- Role of Chinese Medicine Monomers in Dry Eye Disease: Breaking the Vicious Cycle of Inflammation.Pharmacology research & perspectives · 2025Review
- Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease.Ophthalmology and therapy · 2025Article
- Autologous blood in the management of ocular surface disorders.World journal of experimental medicine · 2024Review
- Recent Advances in Pathogenesis, Diagnostic Imaging, and Treatment of Sjögren's Syndrome.Journal of clinical medicine · 2024Article
- Efficacy and Safety of Plasma Rich in Growth Factor in Patients with Congenital Aniridia and Dry Eye Disease.Diseases (Basel, Switzerland) · 2024Article
- Use of allogeneic platelet-rich plasma for the treatment of autoimmune ocular surface disorders: case series.Frontiers in ophthalmology · 2023Article
- Autologous platelet-rich plasma eyedrops for severe dry eye disease unresponsive to autologous serum: A prospective single-arm interventional study.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the study was to compare the difference in composition between 100% autologous serum (AS) and 100% platelet-rich plasma (PRP) eye drops and assess their impact on the clinical outcomes after the treatment of severe dry eye (DE) in primary Sjogren Syndrome patients (pSS). MATERIALS AND
methodsThis is an interventional, non-randomized, comparative, three-month study. 22 patients with severe DE in pSS were treated with 100% AS (22 eyes) and 100% PRP (22 eyes) eye drops 5 times per day in monotherapy mode. The quantifications of growth factors (GFs) such as fibroblast growth factor (FGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), fibronectin, and substance
resultsSignificant differences were observed in the concentration of FGF (4.42 ± 0.86 vs. 15.96 ± 7.63,
conclusionsDespite the fact that blood derivatives differ in composition, they seem to be effective and safe in the treatment of severe DE in pSS patients. The signs and symptoms of DE were reduced in both groups, but only the mean change in OSDI was statistically significant. A greater reduction in OSDI scores was observed in the PRP group. The obtained results and the composition of haemoderivates may indicate the superiority of PRP in relieving the symptoms of DE in pSS patients compared to AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.